
FDA Approves Expanded Use of AbbVie’s MAVYRET for Acute Hepatitis C
FDA Expands Approval of AbbVie’s MAVYRET® as First and Only 8-Week Treatment for Acute Hepatitis C in Adults and Children Aged 3 and Above AbbVie has received a significant regulatory…












